Smilow and Yale Cancer Center Clinical and Research Town Hall | July 1, 2021

Transcript

• 00:00Alright, well good evening everybody.
• 00:02Welcome to town Hall and just a
• 00:05reminder before I get started.
• 00:06You know, these are meant to engage in
• 00:09and be a community of the wider community,
• 00:12and we're about 2000 people.
• 00:14If you think of the entire
• 00:16community of the Yale Cancer Center,
• 00:19the Smilow Cancer Hospital in
• 00:21our ambulatory care sites, and I,
• 00:23I hope that as these town halls
• 00:25sort of continue to happen,
• 00:27we start sharing and learning
• 00:29about our neighbors.
• 00:30Our metaphorical neighbors,
• 00:31and learn about each other,
• 00:33and perhaps then will lead to sort of
• 00:35more enriched community and engagement.
• 00:37So again,
• 00:38just a reminder that sometimes it may
• 00:41mean why are we doing all of this?
• 00:43Because it is to sort of understand
• 00:45all of all of the different parts,
• 00:48and I'll briefly mention that this week,
• 00:50Lori Pickens and I had the opportunity
• 00:52to visit Torrington Care Center.
• 00:54It was delightful to see all the the
• 00:57busy space and all the the staff and
• 00:59the physicians and the nursing teams.
• 01:01So I think it is such a great
• 01:04community we have.
• 01:05We just need to acknowledge that better.
• 01:07It's in our science whether it's our
• 01:09trainees are nursing staff or care
• 01:11centers in these sessions or these
• 01:12these site time we spend together
• 01:14we spend is to start to get to know
• 01:16each other and then start to get
• 01:18through a more richer space as a
• 01:20result of that we have a lot of things,
• 01:23but I do want to leave 10 to 15 to
• 01:2520 minutes at the end for questions
• 01:27I want to remind all of our speakers
• 01:30to sort of respect that so we can then.
• 01:33Really, our folks can ask questions,
• 01:35and with that,
• 01:36Renee if you want to move to the next slide.
• 01:41Oh, I'm sorry I forgot one more thing.
• 01:43Just a reminder.
• 01:44We don't have town hall in August
• 01:46because I do think everyone should
• 01:49take vacation and often August
• 01:50seems to be our favorite time of
• 01:52the year to take vacation.
• 01:54And we'll reconvene in September alright.
• 01:56New appointments,
• 01:57effective June 2021 these are.
• 01:58This is why we are here.
• 02:00You know this is the
• 02:02test stuff you celebrate.
• 02:03So it's really my pleasure to
• 02:05announce our new Chief of Pediatric
• 02:07Imunk and BMT service,
• 02:08or bone marrow transplant service
• 02:11Doctor Lakshman Krishnamurthi was
• 02:13just appointed recently and he will
• 02:15be starting with us on October
• 02:171st 2021 Doctor this recruitment
• 02:19was led by Doctor Cliff Bogart,
• 02:22Chair of Pediatrics and Doctor
• 02:24Krishnamoorthy is an accomplished
• 02:25pediatric hematologist oncologist
• 02:27and an international leader in
• 02:29bone marrow transplant and the
• 02:32treatment of hemoglobinopathies.
• 02:33He's coming to us from Atlanta,
• 02:36where he's professor of Pediatrics at
• 02:39Emory University School of Medicine.
• 02:41Director of the BMT program.
• 02:43I think we also want to thank Doctor
• 02:46Farzana push anchor who has been
• 02:48interim chief of PT Monk and I think
• 02:51I just learned this afternoon that
• 02:53not only is Doctor Krishnamurthy
• 02:55coming but his wife is joining us
• 02:58in the Department of Pathology so we
• 03:00really get our lucky and privileged that
• 03:02we get two in one so they will both be
• 03:06joining in the cancer space in October.
• 03:08Next is Doctor John Visal Marske who has.
• 03:11Been a long standing member of our community,
• 03:14but it was recently appointed section Chief
• 03:17of Endocrinology and Metabolism in the
• 03:19Department of Internal Medicine following
• 03:21a three year stint as our interim chief.
• 03:24He is a member of our Yale Cancer
• 03:26Center Signaling Network research
• 03:28program and also clinically as the
• 03:30part of our endocrinology program,
• 03:32so really excited that John is taking
• 03:35the leadership permanent leadership
• 03:36and then many of you saw the recent
• 03:39appointment of Doctor Barbara Burtness.
• 03:41Who is Professor of medicine as the
• 03:44interim associate Director for Diversity,
• 03:45Equity and inclusion?
• 03:46This is a new position and this is one
• 03:49that many in the Community are broader.
• 03:51Community felt strongly about
• 03:53the entire past year.
• 03:54There was a committee led by Harriet Cougar,
• 03:56along with Kevin Billingsley
• 03:58focused on that and they suggested
• 04:00this and as a result of that,
• 04:02we've had Doctor Burtness
• 04:03appointed as an interim,
• 04:05and you're going to hear
• 04:06from Barbara later today.
• 04:07So I don't want to give her Thunder away,
• 04:10but you're going to see.
• 04:12Why we all believed that she was the right
• 04:15leader to help us launch this program?
• 04:17But she has great leadership and
• 04:19innovative ideas and how to create
• 04:22a more inclusive workplace which
• 04:23then leads to you know engagement
• 04:25and why we all come to work.
• 04:27So with that next slide.
• 04:30OK,
• 04:30more new appointments.
• 04:31Doctor Marcus Bosenberg is also
• 04:33a new announcement you saw,
• 04:35and this is also he's the inaugural director
• 04:37of the Yale Center for Immuno Oncology.
• 04:40This is a bridge program which
• 04:42is you know part of living in a
• 04:44large robust universe as ours.
• 04:46As we live in the hospital.
• 04:48But we also live in the school and also
• 04:51the university and this bridge program
• 04:53links are a cancer menology program
• 04:55with the Department of Immunobiology
• 04:57and to take all the science the wonderful.
• 05:00Clients and translate it so no one
• 05:02could think of a better leader
• 05:04than Marcus and Doctor Rosenberg's
• 05:05research achievements and leader
• 05:07Exploder ship experience will be
• 05:09instrumental for taking us forward.
• 05:11And Doctor Boesenberg is also giving
• 05:13us a little bit of update on what he
• 05:16hopes to accomplish under this new
• 05:18program and then last but not least,
• 05:21it's really my pleasure to announce the
• 05:23appointment of Doctor Kim Blenman as
• 05:25an assistant professor in in medicine,
• 05:27also in medical oncology,
• 05:28doctor Blenman will also have
• 05:30a secondary appointment.
• 05:31In the Department of Computer Science
• 05:34at Yale School of Engineering and
• 05:35Applied Sciences and her research
• 05:37interests is reducing radiation in
• 05:39therapy induced adverse reactions
• 05:41at breast cancer.
• 05:42So really, a wonderful set of
• 05:44accomplishments and then more good news.
• 05:46Next slide,
• 05:47Renee.
• 05:47This is really great news.
• 05:49We had just had an 8.5 million grant from the
• 05:52National Institute of General Medical
• 05:55Sciences, which really answers some
• 05:57other seeks to answer some of the big
• 06:00questions of the so called natural.
• 06:02Apple and this is really how sort of our
• 06:05body takes all of the pieces and makes
• 06:08them sort of work on a day to day basis.
• 06:12In this grant will be is led by
• 06:14Doctor Jason Crawford who's on the
• 06:16West campus in the Yale Institute of
• 06:18Biomolecular Design and Discovery.
• 06:20And then he joined by people
• 06:22in the Cancer Center,
• 06:24including Doctor Noah Palm, Carol Dr,
• 06:26Carolyn Johnson and Doctor Andrew Goodman,
• 06:28who all had researched
• 06:30backgrounds and chemical biology,
• 06:31immunobiology and microbial pathogenesis so.
• 06:33Really, a big news for us as a whole.
• 06:36And then come next slide.
• 06:38Continuing on the theme of good news,
• 06:41Morgan live doctor Morgan Levine
• 06:43just got the 2021 Vincent Christoph
• 06:45Low Rising Star Award,
• 06:47which is given by the American
• 06:49Federation for Aging Research Doctors.
• 06:51AVR Lord became the vice chair of
• 06:53the NCCN colorectal cancer screening
• 06:55guidelines panel Doctor Rachel Greenup
• 06:57got the 2021 National Endowment
• 06:59for Plastic Surgery grant from the
• 07:02Plastic Surgery Foundation fund.
• 07:03Her research on shared decision
• 07:05making for breast reconstruction.
• 07:07Working in partnership with our patients and
• 07:10then Doctor Pam Kunz was appointed
• 07:11as the Journal of Clinical Oncology
• 07:13consultant editor for meeting proceedings,
• 07:16which many of you may or may not know.
• 07:19It's one of the big journals for oncology,
• 07:21so really proud of all of our faculty
• 07:24and their numerous achievements.
• 07:27And just a reminder again for the
• 07:29agenda today it's a packed agenda.
• 07:31Kind of all the site first up
• 07:33will be ambulatory care discovery
• 07:35delivery by Monica Fradkin.
• 07:36And then we'll go to the next
• 07:38part with clinical CT updates,
• 07:40which is a recurring features,
• 07:42then that both the new leaders,
• 07:43Barbara Burtness and Marcus
• 07:45Bosenberg will talk
• 07:46about their new rules. With that, I'm
• 07:48going to turn it over to Monica
• 07:50to talk to us about care delivery,
• 07:52so take it away, Monica.
• 07:55Thank you doctor Hooja.
• 07:58Alright everyone, thank you for
• 08:00allowing me to spend a few minutes of
• 08:02time to share about the great work
• 08:05that has been done around the care
• 08:08delivery workflows and what I'd like
• 08:10to do is just spend a few minutes to
• 08:13talk about the high level work that
• 08:15has been done under the Ambulatory
• 08:18Transformation Committee for the Care
• 08:20Delivery workflow team and really,
• 08:22during this time I'm going to spend
• 08:24a couple minutes to highlight
• 08:26some of the assessments.
• 08:27That have been done as
• 08:29well as the deliverables,
• 08:31the tools and techniques
• 08:32that have been provided,
• 08:33and where we are now.
• 08:35So we will start with just a
• 08:38review of the assessments on how
• 08:40we got here and what we did is we
• 08:44spent a tremendous amount of time.
• 08:46Getting information not only from
• 08:48patients but also from physicians,
• 08:50staff from all areas,
• 08:52all disease teams and locations across
• 08:54the different delivery networks.
• 08:56To understand how we were doing and
• 08:59this was done at the you know last year.
• 09:03But really what we found is that
• 09:05there was a tremendous amount of
• 09:08opportunity with the work that's being
• 09:10done for improvement and so based
• 09:13off of the hundreds of responses that we.
• 09:16Received and many open comments,
• 09:19there were six different teams that
• 09:22really became that bubbled to the top
• 09:25around clinic and infusion that we
• 09:27had opportunities for improvement.
• 09:30So just to give you an idea about the
• 09:34broad span of the work that's being done,
• 09:39there are six different
• 09:41multidisciplinary teams.
• 09:42There are 15 team leaders
• 09:44that are supporting the.
• 09:46Work of these six teams we have
• 09:49more than 70 participants and
• 09:51about 20 different providers.
• 09:54Within all of these different teams.
• 09:57The projects are in various stages.
• 09:59There was no way to start
• 10:01all of them at once,
• 10:03so when we give this update
• 10:05as I share this update,
• 10:07there are some teams that have been
• 10:09working for many months and there
• 10:11are some that are just starting.
• 10:13And really what happened is
• 10:15part of this work.
• 10:16Is there were additional assessments
• 10:18and quality improvement methods that
• 10:21we used to gather more information
• 10:23to really dive into the work so
• 10:25that we can optimize optimize
• 10:26what is how we're doing.
• 10:28Our work so each of the teams also
• 10:32had deliverables and here is a
• 10:34snapshot of the different deliverables
• 10:36within the different teams.
• 10:37But there was there's even more that
• 10:40we could provide to information.
• 10:42But for visit scheduling criteria was
• 10:44created to determine what visit type
• 10:46should be in person versus face to face,
• 10:49face to face,
• 10:50versus Tele health.
• 10:51And we customized it based off
• 10:54the treatment modality and that
• 10:56team really created a lot of work.
• 10:58And then we're going to take.
• 11:00That information and use it within
• 11:03the pre clinic prep work and post
• 11:05clinic wrap up and the checkout
• 11:08teams so that's so we can sustain
• 11:11the different workflows that
• 11:12patients have a meaningful visit
• 11:14and that everyone is prepared
• 11:17appropriately. We have optimization of
• 11:20infusion flow and there were two areas
• 11:22that really came to light was around the
• 11:25pril at the pretreatment lab process,
• 11:28as well as looking at advanced release
• 11:31of orders when it's appropriate.
• 11:33And in addition the work that's being
• 11:36done around IQ and Lean TOS will also,
• 11:39you know, was going to support
• 11:41a lot of this infusion flow.
• 11:45Enhancing the patient education experience
• 11:47but also utilizing Tele visits or Tel
• 11:49technology so that we can provide
• 11:51education with patients and families,
• 11:53but maybe not when they're directly
• 11:55in the chair or in clinic,
• 11:57but at home and then diagnostic,
• 12:00imaging, optimization, and timeliness.
• 12:01We know that there's a lot of
• 12:04opportunity around understanding
• 12:05capacity and utilization and how
• 12:07that impacts our care on a regular
• 12:09basis and then really understanding
• 12:11what our volumes and what do we have.
• 12:15Do we have what we need to meet the
• 12:18demand and as well as there are there
• 12:21patients that are going outside of our
• 12:24our organization for these imaging tests?
• 12:27So just going to share some example
• 12:29of some different processes and
• 12:31clinical tools that have been created
• 12:33around the work that's being done.
• 12:35So we looked at cause and effect diagrams
• 12:38to really understand where where each of
• 12:41the work and barriers may come into play.
• 12:44We process mapped the different
• 12:46workflows and this is an example
• 12:48of something that was done for pre
• 12:51clinic prep and visit criteria.
• 12:53We looked at also assessment parameters,
• 12:55so when we're looking at those process
• 12:58mappings really understanding what
• 13:00are the questions and the tools
• 13:01that need to be used.
• 13:03Because this can also be used
• 13:05for the education when we go into
• 13:08our pilot and training phases.
• 13:10Utilizing epic tools that we really
• 13:13didn't realize were available to us,
• 13:15so using those tools to be more efficient
• 13:19as well as examples of a new visit
• 13:22type that was created to be able to
• 13:25use for Tele visits for patient education.
• 13:30And just some additional
• 13:31education that has been provided.
• 13:33And finally,
• 13:34in order for us to do all this,
• 13:37we need to be able to measure it and
• 13:40understand what we're doing is effective.
• 13:42And is it sustainable?
• 13:44So we are with it when it within each
• 13:47one of these groups we will have
• 13:49metrics for each one of them that we
• 13:52can that could be automated that were
• 13:55standardized to the best possible and
• 13:57that we can also measure pre and post.
• 14:00Implementation of these pilots examples
• 14:02is also to ensure that we measure
• 14:05provider staff and patient satisfaction
• 14:07using different surveys and looking at
• 14:10productivity and performance measures.
• 14:12So based off all that,
• 14:14where are we now?
• 14:16So just to give you a little
• 14:19bit of an update,
• 14:21the visit type scheduling criteria
• 14:23and preclinic prep have combined
• 14:25the work that has been done.
• 14:27Now our assessments are completed.
• 14:29Workflows and trainings have
• 14:30been done and we're at the phase
• 14:33of we're ready to pilot.
• 14:34So we've identified those initial sites and
• 14:37we have sites that are in the queue ready
• 14:41once our first site is up and running,
• 14:43the checkout team has three different
• 14:45work groups made up. Of stakeholders,
• 14:48workflows and epic optimizations,
• 14:50and really what they've done is they've,
• 14:53you know, used our resources of NCCN
• 14:56using best practices that you know
• 14:58the best practice committee to glean
• 15:01information we they've created,
• 15:03created a completed additional workflows and
• 15:05surveys of not only physicians and providers,
• 15:09but also the access staff so they can
• 15:12really understand what's being done
• 15:15where and and to understand that.
• 15:17Workflows.
• 15:18And using Epic in what I TS UM
• 15:21solutions could be available,
• 15:24so they're they're they're working
• 15:26through that as well right now and
• 15:29will really come up with some options.
• 15:32Optimal workflows for this that is using
• 15:35the disposition and the enhancing the
• 15:38checkout process to ensure nothing gets
• 15:41missed from a patient safety standpoint.
• 15:43And then the video enabled patient education.
• 15:46You know, tools are developed
• 15:47in 3 pilots or in progress.
• 15:50You can see that what's listed.
• 15:52The infusion flow optimization is reviewing,
• 15:55you know,
• 15:56has been involved with the IQ lean
• 15:59TOS initiative and other relatives.
• 16:02They've also come.
• 16:03Done some clinical optimal observations
• 16:05for pre releasing the different
• 16:07out for chemotherapy so we can
• 16:10have a real good understanding of
• 16:13current state and to understand
• 16:15where the opportunities would be.
• 16:17And finally diagnostic imaging
• 16:18optimization is really around.
• 16:20As I mentioned,
• 16:21they're creating a dashboard for
• 16:23utilization and capacity and
• 16:25what will that will allow is
• 16:27to understand where are where.
• 16:29We have opportunities to fill slots more.
• 16:32Or do we have?
• 16:33And over capacity issue in one
• 16:35location where we could maybe
• 16:37shift some of the imaging tests to
• 16:40other to other areas that are under
• 16:43capacity and then really looking as I
• 16:46mentioned earlier around the volumes.
• 16:48And the location of the outmigration.
• 16:51So in a real in short,
• 16:53that is the care delivery.
• 16:56Work group is a highly engaged team
• 16:58of a lot of different people that
• 17:01really want to take the opportunity
• 17:04to improve workflow and processes.
• 17:06And you know,
• 17:07I am speaking on behalf of many and
• 17:10that it really has been a great
• 17:13way to bring teams together,
• 17:16understand cross teams workflows
• 17:17and identify best practices,
• 17:19but also realize that.
• 17:20We could do some things better and
• 17:23utilizing the tools that are out
• 17:24there and taking a fresh look so.
• 17:28Thank
• 17:29you Monica, UM, for that update.
• 17:31I think I'd like to keep the questions
• 17:33for for the end for the entire panel,
• 17:36so will will ask the attendees to save
• 17:38the questions and start typing them.
• 17:40And then if you can answer them directly,
• 17:43that's also OK. With that,
• 17:44I'm going to turn it over to Doctor
• 17:46Herbs and just a reminder just to
• 17:49leave Question Time for Q and I'm
• 17:51just going to remind everybody.
• 17:53Keep keep the presentations brief
• 17:54so we can leave more time for Q&A.
• 17:57Doctor Herbs please.
• 17:59Yeah thanks Nita, Uhm can you hear me?
• 18:01We can thank you.
• 18:03Yeah, I'm I'm here in Hartford with
• 18:05the Hartford Care Center team or having
• 18:08a celebration for Jonathan Sporn.
• 18:09I'm sitting outside.
• 18:10Hopefully it doesn't rain first.
• 18:12I want to welcome Mary Ann Lessburg.
• 18:15Today was her first day,
• 18:16though it hardly seems like that
• 18:18because Maryann has been engaged
• 18:20ever since the minute we met her,
• 18:23she'll be leading the breast
• 18:24disease Center breast,
• 18:25medical oncology and we're so
• 18:27happy that you're on campus.
• 18:29Today, Mary Ann sorry,
• 18:30I didn't get to see you today
• 18:32I'll find you tomorrow.
• 18:33Uh, but uh, this is really a great recruit.
• 18:35Mary Mary had comes to us from
• 18:37Ohio State and, uh, well,
• 18:38I hope you'll all get to meet
• 18:40her very soon as we continue
• 18:42to build our breast program.
• 18:43Next slide, please.
• 18:46So I'm here to talk about clinical
• 18:48trials and give you a very brief update.
• 18:51July 1st update next slide.
• 18:56So I just wanted to just bring up why we
• 18:58conduct clinical trials and this is taken
• 19:01from the ICR website on some of these
• 19:04images and some from the YCC website.
• 19:06You know we're forced
• 19:07collaborating very closely,
• 19:08and you can see it's it's about education.
• 19:11It's about science and research.
• 19:13We want better treatments.
• 19:14We want to bring medical
• 19:16breakthroughs to the public.
• 19:17It really is important to think about
• 19:19clinical trials for the cutting edge,
• 19:21best clinical care and also by
• 19:23thinking about a clinical trial.
• 19:25One has to think about the best standards of
• 19:28care so it increases our quality of care.
• 19:31And a reputation and the next slide.
• 19:33You'll see this examples
• 19:34of how it helps patients,
• 19:36and several of these.
• 19:37In fact, I think most of them
• 19:39are Yale cancer patients who have
• 19:41benefited from clinical trial.
• 19:47Next bye. Safe and efficient trials network.
• 19:52We're working on that we're offering.
• 19:54Our systems were improving our standard
• 19:56operating procedures when processes
• 19:58that ensure increased investigator
• 19:59responsibility and oversight,
• 20:01we are now almost completely electronic.
• 20:03That's been along coming,
• 20:05but it's it's been great and we're recruiting
• 20:08a there's a lot of recruiting going on.
• 20:11I've interviewed someone today,
• 20:13focus on education and training
• 20:15of our staff at all levels.
• 20:17We're gonna do some retraining.
• 20:20Everyone needs to constantly be up on the
• 20:23regulatory data and we want to focus on
• 20:26activation of trials and closure of traps.
• 20:28Cloudsat, arner,
• 20:29crewing should be closed and
• 20:31we need more trials obviously,
• 20:33but selective activation.
• 20:34The trials that will really accrue
• 20:36across our network next slide.
• 20:41So just a little bit of
• 20:42good news, I got this.
• 20:46Our activation team just about 2 hours ago.
• 20:49There are 57 studies that are
• 20:52active in the startup process,
• 20:5490 percent, 90% complete.
• 20:56You see eight studies, 75% complete,
• 20:5813 studies and 50% complete for keen study.
• 21:03Opening a trial is like a scavenger hunt.
• 21:05There's so many different things to find.
• 21:07All I ask is everyone who's involved
• 21:10in trials on this Co-op work together
• 21:12and through your calls do your yrag.
• 21:14Let's get these things open 'cause
• 21:16these trials are for our patients,
• 21:18but we are working together as a team.
• 21:21Our regulatory team.
• 21:22We've got some outside stuff
• 21:23from your own who are helping us.
• 21:25Otherwise, CCI team Sarah and CTO team.
• 21:30Thank you everyone for doing this.
• 21:32We are getting trials open it it is.
• 21:37B grade new academic year.
• 21:39Next slide.
• 21:42Next slide, please.
• 21:43Uhm, so these are just two trials
• 21:45that were active this month is a
• 21:47third that I've been waiting for a
• 21:48phone call here on my other phone.
• 21:50I haven't gotten it yet,
• 21:51but any minute it's about
• 21:52to be another cell therapy.
• 21:56But ah.
• 22:00Roy, you're breaking up. I don't know if
• 22:02we're working very hard.
• 22:05OK. Next slide, please.
• 22:09And these are just the numbers.
• 22:11These are, our patients are on trial and
• 22:13I just show this to show you normally
• 22:15of the number of patients that we
• 22:18have on trial and and their accrual.
• 22:20This is as of last week,
• 22:22so we had about 50 patients
• 22:23accrued each year and that's good,
• 22:25but I'd like to see better,
• 22:27so I just implore everyone out there.
• 22:29Whether you're a patient,
• 22:30whether you're a physician,
• 22:31whether you're a nurse or
• 22:33a staff in the clinic,
• 22:34sink about clinical trials.
• 22:35Of course we would love
• 22:37to have more trials open,
• 22:38but we have plenty of trials open,
• 22:40so I think is there a trial that will work?
• 22:42Let's figure out how to make that happen,
• 22:44and then I think on the last slide.
• 22:48Uhm, thank you to our staff.
• 22:50Ummar newsletter will go out
• 22:52hopefully tomorrow morning and,
• 22:53uh, Mandy is one of the people
• 22:55we've spotlighted this month.
• 22:57Each month we're spotlighting
• 22:58some of the staff.
• 22:59It's you that are doing the work,
• 23:01and I really appreciate everyone
• 23:03coming together as a team to help
• 23:05our patients and to help fight
• 23:07this terrible disease of cancer.
• 23:09I think that's the last slide.
• 23:12And I'll just answer questions
• 23:14as long as it doesn't rain.
• 23:16Thank
• 23:16you Roy. Doctor Herbst and thank you
• 23:19to you and the entire team and I know
• 23:22that this is reflected in the work that
• 23:24we do in taking care of her patients.
• 23:27So again, I think it's nice to
• 23:29get the updates monthly so we can
• 23:31then just all sort of work towards
• 23:33optimizing our clinical trials network.
• 23:35Alright, I think next is Doctor Burtness
• 23:38talking about Diane her new role.
• 23:46Thank you need
• 23:47a UM, you know, for the opportunity
• 23:50to to work on on these issues
• 23:52and for the introduction.
• 23:54So I wanted to be brief
• 23:56because we are just starting,
• 23:58but the first thing that I wanted
• 24:00to say is I think inclusion is
• 24:02really a core value for all the
• 24:05components of the El Cancer Center.
• 24:08The Yale School of Medicine.
• 24:09Very explicitly, you know you know,
• 24:11envisions and inclusive community,
• 24:13where everyone's voice and contribution
• 24:16will be valued and respected.
• 24:17And we create a sense of belonging for all,
• 24:22and Yale.
• 24:23New Haven Health sees diversity
• 24:25and inclusion is important.
• 24:28Components of organizational values
• 24:30and is committed to providing
• 24:32an environment of inclusion.
• 24:34That's for patients, visitors,
• 24:36employees, suppliers, the community,
• 24:38and Yale.
• 24:39New Haven Health actually has won
• 24:42many accolades for its support of
• 24:46LGBT health for fostering a diverse.
• 24:49Workforce so we start.
• 24:51I think with a lot of strengths.
• 24:55Uh, let's see.
• 24:59Uh.
• 25:03Don't miss slides. So
• 25:06what are sort of?
• 25:08What are some of the challenges going to be?
• 25:11UM, as we attempt to?
• 25:14Make sure that we're as inclusive as
• 25:16possible, that we treat everybody
• 25:18as equitably as possible and that
• 25:21we're as diverse as possible and
• 25:23and so the first thing I think is
• 25:26understanding where we are.
• 25:28So I think you know,
• 25:30don't be surprised if we undertake some
• 25:33climate surveys or focused interviews
• 25:35so that we understand where we need to
• 25:38focus efforts on growing and changing.
• 25:40And I think one of the things
• 25:43probably the NCI is.
• 25:45Can expect from us one of the
• 25:47things the school may expect from
• 25:49us or the health system.
• 25:51If we're asking for resources,
• 25:52is to be tracking metrics about
• 25:55how we're doing overtime.
• 25:56I think Nita started out by by talking
• 25:59about how important communication is
• 26:01to building a sense of community,
• 26:04and I think that that's particularly the
• 26:07case for members of our Community who
• 26:09may wonder if they're fully accepted,
• 26:12or if they, if they're fully incorporated,
• 26:14so we will be having a part of
• 26:17direct connect every two weeks.
• 26:20Is is hopefully going to be
• 26:22highlighting successes in in diversity,
• 26:24equity, and inclusion,
• 26:25but even if they're not.
• 26:27Some huge steps forward.
• 26:29We will be trying to highlight resources
• 26:32and and and work that's ongoing.
• 26:35Many of us have participated
• 26:38in implicit bias training,
• 26:40either online or facilitated in person,
• 26:43but I think that repeating that
• 26:47potentially looking at it more extensive.
• 26:51Trainings and potentially more levels
• 26:54of the organization may be something
• 26:57that is worth thinking about.
• 27:00Certainly at the Med school and Residency
• 27:03and fellowship level across the country,
• 27:05there is a lot of work on bringing
• 27:08the eye issues into the curriculum.
• 27:12And so we'll be working with the
• 27:15education leaders on those things.
• 27:17Uh,
• 27:17I think one of the things that we
• 27:19want to see from our leaders is
• 27:22that they're successful in fostering
• 27:23an inclusive culture,
• 27:25and we want to be transparent
• 27:27when there are some.
• 27:29Issues of harassment or people
• 27:31or are having difficulty getting
• 27:33their their footing because they
• 27:36don't feel included.
• 27:37We want to be able to address that.
• 27:42We, uh, I think, recognize that among our.
• 27:50Faculty in particular.
• 27:52There are fewer investigators
• 27:54who come from groups that are
• 27:57underrepresented in medicine and science.
• 27:59Then we would wish,
• 28:01and so I anticipate in this probably
• 28:05will will roll onto the person who
• 28:08takes this role permanently after me,
• 28:12but that there will be a focus
• 28:15on recruitment and using a broad
• 28:18definition of excellence that.
• 28:21Some permits us to look around the
• 28:23country at a variety of institutions
• 28:25to identify people who could
• 28:27enrich our community,
• 28:29and then when investigators arrive here,
• 28:31make sure that there is mentorship
• 28:33and community that there are internal
• 28:36funding opportunities that if the
• 28:38COVID related story has been obviously
• 28:40very big for women and investigators
• 28:43of color over the past year,
• 28:45hopefully that's not going to
• 28:47be something that's in our
• 28:49future forever.
• 28:51Making sure that everyone has equal
• 28:53access to leadership opportunities and
• 28:55that we keep the conversation going.
• 28:57This is work that is going on across
• 29:01the university and across the school,
• 29:03and there are many people who are very
• 29:06passionate about it at many levels
• 29:08of the organization I just wanted to
• 29:11highlight three people from Cancer
• 29:13Center divisions and the Cancer Center
• 29:16leadership who are particular champions.
• 29:18So first of all, Harriet Kluger.
• 29:21Who headed the Committee for the past year,
• 29:24identified the need for
• 29:26an associate director.
• 29:27Really, I think passionately made
• 29:29the case and has been so effective as
• 29:32our associate Director of education
• 29:34training and faculty development and
• 29:36clearly issues of diversity are very
• 29:39important for education and faculty
• 29:41development and we hope to continue
• 29:44working with her and then two vice
• 29:47chiefs and hematology and oncology
• 29:49for dirs irisys Sophie and Pam Kunz.
• 29:52And then I just come.
• 29:54There are a lot of resources and they
• 29:58are all over the health system website.
• 30:01They are all over the Med school website
• 30:04and I just wanted to highlight a few
• 30:08the diversity and inclusion page on
• 30:11the Yale New Haven Hospital website,
• 30:13the minority organization for retention
• 30:15and expansion is a faculty group
• 30:18which works on welcoming investigators
• 30:20and faculty from underrepresented.
• 30:22Groups the Committee on the Status
• 30:25of Women in Medicine,
• 30:26which I've been a member of for
• 30:28about seven years.
• 30:30Has worked on many issues with regard
• 30:33to faculty leave compensation,
• 30:35representation on search committees and
• 30:38remains. I think a really strong ally.
• 30:42There is a Yale LGBTQ affinity
• 30:44group and you can link up with
• 30:47that through that website.
• 30:48The Dean has an Advisory Council
• 30:51on LGBTQ I plus affairs,
• 30:53and they also maintain an out list
• 30:55and I many people have already reached
• 30:58out to just say welcome to me.
• 31:01In this role.
• 31:02A few who have reached out because
• 31:05you have stories that you think
• 31:08it's important that I hear and I
• 31:10just wanted to to say bye.
• 31:13At least my virtual door is always
• 31:14open and I hope people will reach
• 31:16out to me and I hope to come back
• 31:19to you with more stories and in
• 31:21a couple of months. Thank you.
• 31:24Thank you Doctor Burtness and I also want
• 31:26to point out that Kim Slusser is also
• 31:29leading an effort for the hospital in.
• 31:31In looking into this from
• 31:32the health system side,
• 31:34and she's leading a committee,
• 31:35so hopefully we can chat and continue
• 31:37to keep this conversation as a regular
• 31:39piece both in smile or direct Connect.
• 31:41And in these sessions Next up is
• 31:43Doctor Marcus Bosenberg was going
• 31:45to talk about the new this new as
• 31:47the novel the director of ICIO.
• 31:50Thanks so much and and I just wanted
• 31:53to acknowledge too that we've actually
• 31:56had a Yale Center for Immuno Oncology
• 31:59since 2018 and Roy Herbst who was
• 32:02recently just presented was the
• 32:04inaugural interim director and I've
• 32:06functioned in that role since 2019.
• 32:09And as I think quite a number of
• 32:11you have noticed that we've had some
• 32:15very successful symposia annually,
• 32:17including over 400 attendees.
• 32:18Last fall there's a seminar series.
• 32:21That's been part of the Human Translational
• 32:24Immunology series of one date,
• 32:25a month up to now,
• 32:27on Tuesday afternoons at four,
• 32:29and we've had a number of working groups
• 32:31over the past year that we will be
• 32:34continuing and expanding in those roles,
• 32:36and I just wanted to give a very
• 32:39brief overview of sort of the vision
• 32:41and thought for the Center for
• 32:43Immuno oncology on a longer basis.
• 32:46And you know,
• 32:47in short the vision is to be the most
• 32:50impactful immuno oncology center.
• 32:51Anywhere, and that's a big and bold goal,
• 32:54and that will require likely some you know,
• 32:56raising money through development
• 32:58and philanthropy which has occurred
• 32:59also at other centers,
• 33:01but it builds on the strengths
• 33:02that we have in our Immunobiology
• 33:04department here at Yale,
• 33:06which is viewed as if not the best
• 33:08one of the very best in the world,
• 33:11and our strengths and cancer.
• 33:12So I think it really is possible with
• 33:15the talent that we have in hand and
• 33:18I just wanted to give an overview
• 33:20slide here of some of the core.
• 33:22Initial areas of interest and core functions.
• 33:25You know in terms of actual core
• 33:28like entities you know.
• 33:29T cell biology is just central
• 33:31to all of cancer immunology.
• 33:34There's many aspects of this.
• 33:36We're also interested in recruiting
• 33:38additional faculty member or
• 33:39members in this area.
• 33:41The tumor microenvironment is a
• 33:43unique aspect of cancer that doesn't
• 33:45occur in other areas of immunology,
• 33:48and those are more on the basic
• 33:50side but also have some.
• 33:52Translational and clinical applications.
• 33:54And then there's some other things
• 33:56that I'm sure in the future,
• 33:58either grand rounds or other fora
• 34:00that I'll explain in greater length,
• 34:02but looking at ways to personalize
• 34:04immunotherapy so that we can avoid
• 34:06immune related adverse events,
• 34:08which is another area where there has
• 34:11been some quite a bit of work at Yale,
• 34:13and I think some strength that we
• 34:16hope to increase efficacy of these
• 34:18agents and reduce side effects
• 34:20from that point of view.
• 34:22And the bottom 5 boxes.
• 34:23Here are core or core like functions that
• 34:26we hope to coordinate through why, CIO?
• 34:29Some of these exist already.
• 34:31Some of you are likely aware of the events
• 34:33cell therapy lab that Diane Krauss leads.
• 34:36There's a Center for
• 34:38precision cancer modeling,
• 34:39wish musami and myself have led that
• 34:41a number of you have used that.
• 34:44Does preclinical testing you know,
• 34:46including of immune oncology
• 34:47agents and we'd like to coordinate.
• 34:49And this is to add onto and to help make
• 34:52even more efficient.
• 34:54Some existing functions in light
• 34:56of an immune monitoring core
• 34:58informatics capabilities at Yale.
• 34:59But to make it easier for investigators
• 35:02that are IO oriented to do their
• 35:05work and also we'd like to add the
• 35:08ability to collect biospecimens,
• 35:09for instance bloods,
• 35:11prior to immune therapy,
• 35:12and this would add onto existing
• 35:14efforts at Yale by a number of people,
• 35:18including in Harriet, Kevin,
• 35:19Harold and Pat La Russo and others are now.
• 35:23We're also trying to do this.
• 35:25In in this space and so how
• 35:28are we going to do this? Well,
• 35:30you know there will be some new factor rooms.
• 35:33There are actually two
• 35:35slots that are currently.
• 35:36We had made an announcement last May and
• 35:39had made some recommendations in terms of
• 35:42candidates which are still in process.
• 35:44Now that will likely continue
• 35:46and we anticipate that this will
• 35:49continue over the next few years
• 35:51with a couple hopefully more
• 35:53slots happening over that time.
• 35:55And then the other part.
• 35:56That's really a core aspect of why CIO is
• 35:59to help yell faculty get into this space,
• 36:02get funding,
• 36:02learn about what they can do in this,
• 36:05and to come to pair them up with
• 36:07collaborators that are effective in
• 36:08both their discovery and grant funding.
• 36:10And you know,
• 36:11I think that's a real core aspect with all
• 36:14the talent we have at Yale to help others.
• 36:17So to add value by,
• 36:18you know,
• 36:19enabling the folks that are here at Yale,
• 36:21and to provide or recruit additional
• 36:23folks where there are areas.
• 36:25Or might be a little bit
• 36:27later in terms of depth,
• 36:28and I'll I'm actually looking forward to
• 36:31speaking with a number of you individually.
• 36:33I'll be reaching out on that basis,
• 36:35but anytime individuals would like to.
• 36:38Give input about what they think,
• 36:40why CIO should be doing.
• 36:42I'm always list ready to to to talk
• 36:43or or have a conversation about that
• 36:45and we will making some announcements
• 36:47about pilot funding over the next
• 36:49several months and it will be helpful
• 36:52to be AY CIO member to do that.
• 36:54Which basically is submitting a
• 36:56biosketch and a small paragraph
• 36:58about why you'd want to be a member.
• 36:59It's a pretty low bar in terms of
• 37:02trying to get people to be interested,
• 37:04but that would be one of the
• 37:06things that will be doing,
• 37:08and so I will stop.
• 37:09Hearing and allow for enough time
• 37:12for questions,
• 37:13hopefully.
• 37:14Thank you so much and thank
• 37:16you to all our panelists.
• 37:18I think I'd like to open up
• 37:20the agenda now for question,
• 37:22for Q&A and so folks can start
• 37:24typing it in the chat box.
• 37:26But while they're doing that,
• 37:28maybe Monocle asks you a question as we
• 37:30as as we wait for people to chime in.
• 37:33I guess you know clearly a lot
• 37:36of people are curious as to how
• 37:38implementation will happen and
• 37:39how do we and I think part of
• 37:42it reflects our sites, right?
• 37:44We are big insights.
• 37:45In scope, and we also then have
• 37:47so many different disease.
• 37:49So how do you see that?
• 37:51Taking across you know from?
• 37:53In terms of the different phases,
• 37:55because I think that could,
• 37:56there's a lot of interest in this
• 37:58because this effects all of her life.
• 38:00So maybe if you can spend a couple
• 38:03minutes on that Monica and I
• 38:05actually will start off with some.
• 38:07Each of our work groups has
• 38:09representation from not only the
• 38:11network and but the main campus
• 38:13and the different disease teams,
• 38:15as well as all the different roles.
• 38:17So we were purposeful in determining
• 38:19who was going to participate in each
• 38:22of the groups so that we had act
• 38:24adequate representation across all
• 38:26treatment modalities as well as areas.
• 38:29And we will do this in phased approach,
• 38:31so we'll start small with pilots
• 38:34because it's very easy to.
• 38:37Modify workflow changes or processes when
• 38:39you start with a small team and then
• 38:42as we get better and smoother we will
• 38:46implement that slowly over different
• 38:48disease teams as well as locations
• 38:51and I can tell you that each of the teams.
• 38:56Everything that one size doesn't fit
• 38:58all because we know that surgery is
• 39:00going to be different than radiation
• 39:02versus Med ONC and we have to be
• 39:05thoughtful and identifying what are
• 39:06the key elements within whichever
• 39:08team it is that we will are.
• 39:10The are the core elements of that
• 39:12work and then it may look a little
• 39:14different within how it is with
• 39:16rolled out within surgery.
• 39:18Or you know a specific disease,
• 39:20team or location.
• 39:21So we'll start small and
• 39:22we will continue to add it.
• 39:24So it's going to take a lot of times.
• 39:27Come to be able to do this work.
• 39:31So I see Kim Slusser has also joined
• 39:33us and maybe Kim would like to add some
• 39:35other comments or if there is any other
• 39:37things you'd like to highlight him. Uhm,
• 39:41no. I I agree with what Monica said.
• 39:44I think the most important piece and
• 39:46I know Monica said it a couple of
• 39:48times is that there is engagement
• 39:50across all disciplines and all sites.
• 39:53And we do recognize that the work
• 39:55may look different within the teams,
• 39:57but the core principles of what
• 39:59needs to be done to ensure all
• 40:01the team members are prepared for
• 40:03clinic to take care of patients
• 40:05that adequate coordination of care
• 40:07happens and that we have efficient
• 40:09workflows because everybody is really.
• 40:11Aligned in the work,
• 40:12I think that's the power of these workgroups.
• 40:15It's coming together to determine what
• 40:17those needs are for patients and for
• 40:19our teams and then creating workflows
• 40:20to make that happen efficiently.
• 40:22So, as Monica said,
• 40:24it's going to take some time
• 40:26to get across to all areas,
• 40:27but I think with each implementation as well,
• 40:30we will learn more and will
• 40:32keep adapting as we go.
• 40:33And that's a whole piece
• 40:35of the process as well,
• 40:37so it's not kind of this Big Bang.
• 40:39And then there's a lot of problems.
• 40:42That we have to go back and solve.
• 40:43It's that we do this in increments
• 40:45where we're learning as we go.
• 40:48And I'm going to just remind folks
• 40:50to type in their questions and the
• 40:52panel in the chat so we can see it.
• 40:55But perhaps the other part.
• 40:56You know, if if they were starting with the
• 40:59pile and given the scope came in and Monica,
• 41:01do you have a timeline in your mind
• 41:03of when you expect to sort of,
• 41:05you know, see, you know we're you
• 41:07know this is 30% of the workforce.
• 41:09So almost again chart where we can say, OK,
• 41:12we know we're on the right track and you
• 41:14know this is like a surgeon talking right?
• 41:17Everybody knows the surgeons.
• 41:18Wanna see you know a timeline but
• 41:20but just sort of bringing it and
• 41:22again all of this sometimes can be
• 41:24we can go a little buffer but I think
• 41:26part of as we start on the journeys.
• 41:28Also thinking about the finish
• 41:29goal and what does that look like?
• 41:31Not that you ever finish,
• 41:33but I'm going to put you out there a
• 41:35little bit just to sort of 'cause I
• 41:37know many people are probably eager to
• 41:39hear more. Yeah sure.
• 41:40I think the complaint.
• 41:41The one thing to think about is
• 41:43the complexity of each of the work
• 41:45groups so we know that there's
• 41:47a lot of effort and focus on.
• 41:48The checkout process and how can we
• 41:51make sure that the discussion and
• 41:53plan with the patient in the during
• 41:56the clinic translates to someone
• 41:58doing the next steps of that visit,
• 42:01whether it's scans, imaging, referrals,
• 42:03labs you don't or no follow up.
• 42:06And So what are the and we have
• 42:09to understand what's out there
• 42:11for us to use so that we can work
• 42:14smarter and that we're not putting
• 42:17burden on one specific person?
• 42:19So I'm gonna say that the
• 42:21checkout process is going to be.
• 42:23A much longer process potentially
• 42:25than the work that we're going
• 42:27to do around the pre clinic prep
• 42:29and the visit criteria so,
• 42:31so we're already starting the pilot for that,
• 42:33but I know that the work that's being
• 42:36done around check out or infusion
• 42:38may take longer and it's only
• 42:39going to affect pockets of people.
• 42:42So I would say that it's months of going,
• 42:44you know, picking away at this,
• 42:46but can I tell you that will all
• 42:49be done by the end of the year?
• 42:51Or I I can't give it?
• 42:54Timeline
• 42:54for no. And then I don't expect
• 42:55you to, so I I don't like.
• 42:57I would like to I would
• 42:58like to say you know what?
• 43:00By December 31st we're gonna
• 43:01have all this work done so that
• 43:03we can move on to the next part,
• 43:04but that's not the reality.
• 43:05So but I can tell you that.
• 43:08You know we've had, UM,
• 43:10the group of people that are participating
• 43:12are so engaged they attend our meetings,
• 43:14there's homework with each of our groups.
• 43:17They come back with the information
• 43:19because we asked them to go back
• 43:21to different teams and stakeholders
• 43:23to ask for feedback on things
• 43:25that we're working on.
• 43:26And all that is done.
• 43:28So it is.
• 43:29It is really I'm speaking on the
• 43:31work of many that are really spending
• 43:34a lot of time on this so that it
• 43:37is really valuable in the end.
• 43:39We don't want you know.
• 43:40The worst,
• 43:40the last thing we want is to spend
• 43:42a tremendous amount of time and
• 43:44then not see impact at the end, so.
• 43:47And I would just say that I think as we
• 43:49launch and we mentioned this last month
• 43:52that Kevin Billingsley and I are getting
• 43:55ready to launch the Clinical Council.
• 43:56I think that will be one venue that the
• 43:59ambulatory transformation team will be coming
• 44:01to on a regular basis to give updates.
• 44:04And then these town halls to continue
• 44:06to come back and give updates because
• 44:08I think it's important for the teams
• 44:10for all the teams to know where
• 44:13we're at and the progress.
• 44:14And as Monica said, all of these work.
• 44:17Close will have metrics attached to them,
• 44:19and that's critical to to know
• 44:21how much we are improving.
• 44:23You know our operations and our care
• 44:25delivery for our patients so and and and
• 44:27the environment in which our teams work.
• 44:30So I think that that's just critical
• 44:32to have those venues and I would
• 44:34say if there are areas that want
• 44:36to hear in more detail about the
• 44:38specific initiatives you know,
• 44:40please reach out and we
• 44:41can make sure that we have.
• 44:43There are lots of the leaders
• 44:45have been going on the road.
• 44:47So to make sure that everyone knows the
• 44:50work that's being done and that can and
• 44:53that they can contribute to that work.
• 44:55So don't be shy and just let us know.
• 45:00Thank you in Monica and Monica, Renee.
• 45:02If I miss any questions
• 45:04please keep me honest.
• 45:05I think the other part Barbara.
• 45:07I know you mentioned in your chat
• 45:09in your conversation that many
• 45:10have already reached out to you,
• 45:12but if people want to reach out to you,
• 45:14I presume it be nice to highlight your email.
• 45:17I presume most people know how to
• 45:19get in touch with you, but if not,
• 45:21I'll ask Renee to highlight that information.
• 45:23I was thinking about that that we
• 45:25probably want to make sure people
• 45:27know how to reach you easily and I
• 45:29don't know if.
• 45:30If if the slides get shared on,
• 45:33people can find it, but it was.
• 45:35It was the last resource on the
• 45:37slide and it's Barbara. Ducker will
• 45:38share so people can. I
• 45:40know you're just both.
• 45:41You and Marcus are just beginning
• 45:43the journey, so I don't want
• 45:44to put you on the spot, right?
• 45:46I'd like to come back with one
• 45:48question and I know many people I've
• 45:50been listening to various groups,
• 45:52the Clinical Trials Office are
• 45:53physicians who are on the front
• 45:55lines as well as the leaders,
• 45:57and I guess as I'm learning about the
• 45:59clinical trials, I'm stuck by how many.
• 46:01Details are there.
• 46:02A lot of people have expressed
• 46:04their desire to help.
• 46:05How can they help us?
• 46:07I mean, I think you mentioned some of this.
• 46:10You know, answer those you know.
• 46:11Get those things.
• 46:12Perhaps you can speak a little bit on that.
• 46:15How can folks help?
• 46:16'cause I know there's a big
• 46:18desire to make these things you
• 46:20know start activate on time.
• 46:22But how can folks help you
• 46:24and look CTO office? Thanks.
• 46:25That's a very good point.
• 46:27There's so many processes involved
• 46:29in getting trials activated,
• 46:30and it often involves.
• 46:31Input from the dark until investigators,
• 46:34what's? What's it?
• 46:35What's a billable item for
• 46:37a clinical versus research?
• 46:38Sometimes you need a form style 1572.
• 46:41There have been people who have had
• 46:44expired trainings, so when you get
• 46:46an email from the CTO for that,
• 46:49please try to do it right away.
• 46:52Work with your administrative support.
• 46:54We really need that.
• 46:56Things like filing the actual paperwork.
• 46:58I'd rather have a CTO team do you.
• 47:01You know,
• 47:02I know people have offered to do that too,
• 47:04but I think we should have, you know,
• 47:07the regulatory work is so precise,
• 47:08will have the team do that,
• 47:10but we do have so many things that go
• 47:12back and forth and everything takes time.
• 47:15You know, it's it's like any other project.
• 47:17Project management is so important
• 47:18we're making progress.
• 47:19We have.
• 47:20We're hiring more regulatory
• 47:21staff of our own.
• 47:22We already have some amazing people you know,
• 47:24like basically.
• 47:25And then we're also bringing
• 47:26in extra help from your on.
• 47:28But we need the investigator that
• 47:30the dark teams, uh, the nurses.
• 47:31That the staff to all they'll be engaged,
• 47:34and it also doesn't hurt to push you.
• 47:36I don't mind people pushing.
• 47:37I push you have your trial.
• 47:39It's your research, you know,
• 47:40make it happen and again,
• 47:42you know with limits.
• 47:43But we want to try to get
• 47:45these things going in,
• 47:46and I'm certainly I'm an investigator
• 47:48myself so I know what it means and I care.
• 47:51And I'm certainly around to help as well.
• 47:54Thank you doctor.
• 47:55So I mean it's positive engagement and
• 47:57we want though all the oars rowing in
• 47:59the same direction than any comments
• 48:00from you on the broader things.
• 48:02I think we had a lot of good news.
• 48:05Anything else you want to point out?
• 48:07I know you're here and joining us on
• 48:09the panelist here. No,
• 48:10I think we had a good summary today.
• 48:14The director search is ongoing.
• 48:15They understand that they have
• 48:17completed the first round of
• 48:19interviews for a new director.
• 48:21And we make a recommendation,
• 48:22or at least a list of suggested names
• 48:24to the Dean by the end of the month.
• 48:26And that in the meantime,
• 48:28we are proceeding with our renewal for
• 48:30the major Cancer Center support grant.
• 48:32Will get were actually just this week
• 48:34we started giving instructions to
• 48:35write to start writing the new grant.
• 48:38So let let going on.
• 48:39Yeah and lot going on
• 48:41and thank you and I think
• 48:43from what I've heard.
• 48:44Although I'm not on the search committee,
• 48:46but I've heard lots of great candidates.
• 48:48So I think the search committee is
• 48:50really excited about our next director.
• 48:52Alright, if there's no more questions.
• 48:54I know it's a long holiday and I want.
• 48:57Sort of safe.
• 48:58We're done 10 minutes or 9 minutes early.
• 49:00I don't think anyone's going to be upset.
• 49:03It's again, I do encourage the folks if
• 49:05they want to ask questions. You know,
• 49:07there's only a certain number of ways,
• 49:09so typing the questions
• 49:10either directly to me.
• 49:11If you don't feel comfortable sharing it
• 49:13with everybody is also a way to do this.
• 49:15I know all of you want to ask questions,
• 49:18so I know you're not shy,
• 49:20but I do encourage you to ask if
• 49:22we don't know what's on your mind,
• 49:24we can't answer that question, so again,
• 49:26hopefully will build up that interaction.
• 49:27And those muscles.
• 49:28But thank you to all our panelists.
• 49:31You're very good.
• 49:31You kept it on schedule and we're even
• 49:34finished a few minutes early, Renee,
• 49:36just I think you wanted me to remind them no,
• 49:39no town hall in August.
• 49:40And if they have agenda items in mind,
• 49:43I think I'm going to get this right.
• 49:45Cancer answers at yale.edu.
• 49:47If you have questions and things you want,
• 49:49see here.
• 49:50Again, if you send us those things,
• 49:52we can bring them up.
• 49:53But if if I if we don't hear from you,
• 49:56then I will kind of.
• 49:58Shooting in the dark,
• 49:59but I will try to bring all the news.
• 50:02Good bad positive news things we
• 50:04want to talk about as a community.
• 50:06So thank you all.
• 50:07Please enjoy the long weekend.
• 50:08If you do have some time,
• 50:10I hope everyone gets some time off this
• 50:12weekend to enjoy and hopefully it'll
• 50:14cool down a bit and everyone can enjoy.
• 50:16So thank you everybody.
• 50:17Thank you to all our panelists.
• 50:19Doctor Hurst.
• 50:20Thankfully we heard you and it
• 50:22didn't rain so it but the clouds
• 50:24back behind you look really dark
• 50:25so I would get inside alright.
• 50:27Take care everybody bye bye.